The Japanese most cancers drug powerhouse Daiichi Sankyo has its sights on the subsequent technology of focused oncology medicine, and this time it may not want a accomplice to get it over the road.
“We’re in a spot now the place we’ve bought lots of the capabilities that we didn’t have 5 years in the past, so I feel the bar for us to contemplate bringing in a accomplice will get larger and better,” Ken Keller, chief govt officer of Daiichi’s’ U.S. subsidiary, mentioned in an interview on the European Society for Medical Oncology.
AstraZeneca and Daiichi’s breast most cancers drug Enhertu relies off of Daiichi’s antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023.
